Targeting of growth factor receptors is an obvious anti-cancer strategy and many drugs are designed towards VEGFR (bevacizumab, sunitinib), EGFR (cetuximab, erlotinib), HER2 (trastuzumab, pertuzumab) and PDGFR (imatinib, crenolanib). The gene discussed is KDR; the disease is cancer.